

**First annual ACT Canada Consortium Meeting
Hamilton Convention Centre
Hamilton, ON
Monday, April 17th – Tuesday, April 18th, 2023**

Monday April 17 th , 2023		
Session 1: 8:00-10:55 Chairs: Marion Campbell and Jean Rouleau		
8:00	Welcome remarks and meeting opening	<i>Elder Allan Loft</i> <i>Nicole Yada</i>
8:10	ACT Canada: <ul style="list-style-type: none"> • <i>Overview of ACT goals and structure</i> • <i>ACT governance</i> Presentation (20 minutes) Audience questions/discussion (10 minutes)	<i>P.J. Devereaux and Guy Rouleau</i>
8:40	Keynote speaker – <i>Clinical trials in a crisis: Learning from the RECOVERY trial</i> Presentation (20 minutes) Audience questions/discussion (10 minutes)	<i>Martin Landray</i>
9:10	Canadian Biotechnology – <i>What is needed to help develop a thriving, large, highly successful ecosystem</i> Presentation (10 minutes) Audience questions/discussion (5 minutes)	<i>Tim Murphy</i>
9:25	Canadian Biotechnology – <i>Made in Canada solutions Pt. 1</i> <i>Biotechnology company presentations</i> (each presentation - 3 minutes; followed by panel question or comment for each biotechnology company - 2 minutes)	<i>Panel: Adrien Cote, Alex Muggah</i>
10:25	BREAK – EXHIBITOR BOOTH WALK ABOUT <i>Interaction between researchers and biotechnology companies</i> Venue (Level 1)	
Session 2: 10:55-13:25 Chairs: Emily McDonald and Tom Marrie		
10:55	Keynote speaker – <i>Ideas to practice</i> Presentation (20 minutes) Audience questions/discussion (10 minutes)	<i>Salim Yusuf</i>

11:25	Canadian Biotechnology – Made in Canada solutions Pt. 2 <i>Biotechnology company presentations</i> (each presentation - 3 minutes; followed by panel question or comment for each biotechnology company - 2 minutes)	<i>Panel:</i> <i>Moazam Khan, Keenan Sarani</i>
12:25	GRAB & GO LUNCH – EXHIBITOR BOOTH WALK ABOUT <i>Interaction between researchers and biotechnology companies</i> Venue (Level 1)	
Session 3: 13:25-16:10 Chairs: Rita Suri and Denis Xavier		
13:25	ACT Scientific Committee – Goals, structure, and Request for Applications (RFAs) <ul style="list-style-type: none"> • <i>RFA 1 – High impact trials</i> • <i>RFA 2 – Novel trial designs</i> • <i>RFA 3 – Canadian biotech trials</i> Presentation (10 minutes) Audience questions/discussion (10 minutes)	<i>Amit Garg and Louise Pilote</i>
13:45	Network Committee – Overview of goals and structure of the ACT Network Committee, portfolio system, and information on ACT networks. Presentation (20 minutes) Audience questions/discussion (10 minutes)	<i>Maureen Meade and Karthik Tennankore</i>
14:15	Canadian Biotechnology – Made in Canada solutions Pt. 3 <i>Biotechnology company presentations</i> (each presentation - 3 minutes; followed by panel question or comment for each biotechnology company - 2 minutes)	<i>Panel:</i> <i>Amol Deshpande, Maura Campbell</i>
15:15	Guest Speaker – Development and clinical testing of biotherapeutics for the treatment of cancer Presentation (15 minutes) Audience questions/discussion (10 minutes)	<i>John Bell</i>
15:40	BREAK – EXHIBITOR BOOTH WALK ABOUT <i>Interaction between researchers and biotechnology companies</i> Venue (Level 1)	
Session 4: 16:10-17:00 Chairs: Faisal Ahmed and Breanne Stewart		
16:10	ACT Indigenous Health Committee - Goals and plans Presentation (10 minutes) Audience questions/discussion (5 minutes)	<i>Wayne Clark and Wanda Phillips-Beck</i>
16:25	ACT Ethics Working Group – Goals and plans (Presentation P.J. Devereaux; 10 minutes)	<i>Panel:</i>

	Panel discussion (10 minutes) Audience questions/discussion (10 minutes)	<i>Erika Basile, Shurjeel Choudhri, Susan Marlin, and Alison Orth</i>
16:55	Day 1 – Summary, Highlights, and Housekeeping	<i>P.J. Devereaux, Guy Rouleau, and Nicole Yada</i>
17:00	Adjourn	

Tuesday April 18th, 2023		
Welcome Day 2 Session 5: 8:00-10:25 Chairs: Flavia Borges and Gavin Stuart		
8:05	ACT Training Committee – Goals and plans of ACT Training Committee (Presentation Bourbeau and Bangdiwala; 6 minutes) Panel discussion of 7 funded CTTs on leveraging and integrating Clinical Trials Training Platforms with the ACT Consortium (14 minutes) Audience questions/discussion (10 minutes)	<i>Jean Bourbeau and Shrikant Bangdiwala</i> <i>Panel of CTT PIs: Simon Bacon, Jasmine Grant, Jodi Edwards, Lauren Kelly, Taylor McLinden, Sameer Parpia</i>
8:35	Systems Transformation Committee – Overview presentation of System Transformation Committee objectives and plans (Presentation Dean Fergusson and Lawrence Richer; 10 minutes) Panel discussion focused on contracts and regulatory issues (10 minutes) Audience questions/discussion (10 minutes)	<i>Dean Fergusson and Lawrence Richer</i> <i>Panel: Jennifer Cox, Sonny Kohli, Frank Naus, Janette Panhuis</i>
8:55	Canadian Biotechnology – Made in Canada solutions Pt. 4 Biotechnology company presentations (each presentation - 3 minutes; followed by panel question or comment for each biotechnology company - 2 minutes)	<i>Panel: Tim Murphy</i>
9:55	BREAK – EXHIBITOR BOOTH WALK ABOUT <i>Interaction between researchers and biotechnology companies</i> Venue (Level 1)	
Session 6: 10:25–13:00 Chairs: Emmanuelle Duceppe and Sanjit Jolly		

10:25	<p>Patient Engagement Committee – <i>Overview of goals, plans, and research</i> (Presentation Stuart Nicholls and Antonia Palmer; 10 minutes)</p> <p>Canadian Heart Function Alliance - <i>Experience in patient engagement</i> (Presentation Marc Bains; 10 minutes)</p> <p>Audience questions/discussion (10 minutes)</p>	<p><i>Stuart Nicholls and Antonia Palmer</i></p> <p><i>Marc Bains</i></p>
10:55	<p>Potential Collaboration with Major Canadian Pharmacy Chain – Panel discussion <i>focused on potential for patient identification, drug purchasing, drug distribution, compliance and outcome data collection</i> (10 minutes)</p> <p>Audience questions/discussion (10 minutes)</p>	<p><i>Tanya Moore, P.J. Devereaux, Michael Walsh, Janarthanan Sathanathan</i></p>
11:15	<p>Guest Speaker - <i>How to convert a scientific discovery into a commercially successful discovery</i></p> <p>Presentation (15 minutes)</p> <p>Audience questions/discussion (10 minutes)</p>	<p><i>Jack Hirsh</i></p>
11:40	<p>GRAB & GO LUNCH – EXHIBITOR BOOTH WALK ABOUT <i>Interaction between researchers and biotechnology companies</i> Venue (Level 1)</p>	
<p>Session 7: 13:00-15:30 Chairs: Catherine Joyes and Denis Prud'homme</p>		
13:00	<p>ACT Canada Insurance Committee – <i>Goals and plans</i></p> <p>Presentation (10 minutes)</p> <p>Audience questions/discussion (5 minutes)</p>	<p><i>Anthony Scandivano</i> <i>Mark McKay</i></p>
13:15	<p>Guest speaker - <i>Venture capitalist (what they are looking for and important issues)</i></p> <p>Presentation (15 minutes)</p> <p>Audience questions/discussion (10 minutes)</p>	<p><i>Ivan Shaw</i></p>
13:40	<p>Trial Units Committee – <i>Overview of goals and structure of the ACT Trial Units Committee</i> (Presentation Justin Ezekowitz and Ryan Zarychanski; 5 minutes)</p> <p>Panel Discussion <i>focused on each of the ACT trial units</i> (22 minutes)</p> <p>Audience questions/discussion (8 minutes)</p>	<p><i>Justin Ezekowitz, Amit Garg, Hertzell Gerstein, Thierry Lacaze, François Lauzier, Jessica McCarthy, Amity Quinn, Sushmita Pamidi, Tim Ramsay, Vishaldeep Sidhu, Ryan Zarychanski</i></p>
14:15	<p>Canadian Facility – <i>Drug packaging, labelling, and shipping</i></p> <p>Presentation (5 minutes)</p> <p>Audience questions/discussion (5 minutes)</p>	<p><i>Kaitlin Guarasci</i></p>

14:25	<p>Canadian Biomedical Research Fund and Canada First Research Excellence Fund Awardees</p> <p>Panel Presentation (21 minutes)</p> <ul style="list-style-type: none"> • Canada’s Immuno-Engineering and Biomanufacturing Hub, led by The University of British Columbia • Canadian Pandemic Preparedness Hub, led by the University of Ottawa and McMaster University • Brain-Heart Interconnectome • DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics <p>Audience questions/discussion (9 minutes)</p>	<p><i>Peter Liu</i></p> <p><i>John Bell, Michelle Wong, Rob McMaster, Guy Rouleau</i></p>
14:55	<p>ACT Consortium / HDRN Canada Working Group – Goals and plans, including how we can establish a process to access administrative data across provinces to facilitate national RCTs (Presentation Amit Garg; 10 minutes)</p> <p>Panel discussion (10 minutes)</p> <p>Audience questions/discussion (10 minutes)</p>	<p><i>Panel:</i></p> <p><i>Amit Garg, Kimberlyn McGrail and Michael Schull</i></p>
15:25	<p>Closing remarks</p>	<p><i>P.J. Devereaux, Guy Rouleau, and Nicole Yada</i></p>
15:30	<p>Meeting adjourned</p>	

First Annual ACT Canada Consortium Meeting - Sponsors

Thank you to our generous sponsors for their support of this meeting:

Platinum Sponsors
<p><i>Sponsor of plenary session</i></p> <p>Bayer IMC Roche</p>
Silver Sponsors
<p><i>Sponsor of meals and breaks</i></p> <p>Bay Area Research Logistics Cytokinetics Lumenix Novo Nordisk Sanofi</p>
Bronze Sponsors
<p>Abbott Edwards Life Sciences Eli Lilly Medtronic Novartis Synapse Life Science Consortium</p>

Thank you to the Canadian Institutes of Health Research (CIHR) for supporting the Accelerating Clinical Trials Consortium.

Presenters and Exhibitors
<p>AeroImmune Biotechnologies Brian Lichty</p>
<p>Inhaled vaccines and anti-virals. Current programs include two candidate next-gen, inhaled multi- antigen COVID19 vaccines, an inhaled multi-antigen TB vaccine (that targets each life stage of TB infections) as we'll as candidate, inhaled pan-influenza vaccines.</p>
<p>AmacaThera Inc Mike Foorer amacathera.ca</p>
<p>AmacaThera is a clinical-stage company transforming therapeutics to make a difference in patient health. AmacaGel™, our unique, injectable hydrogel platform provides localized sustained drug delivery for improved patient outcomes across multiple therapeutic areas, including post-surgical pain management, cancer and other hard-to-reach unmet medical needs.</p>
<p>Ampa Health Jonathan Downar ampahealth.com</p>
<p>Transcranial Magnetic Stimulation (TMS) is a Health Canada-approved, non-invasive brain stimulation treatment used for depression and increasingly for other psychiatric and neurological conditions, with the most recent treatment protocols now offering high remission rates (~70-80%) and rapid effect (5 days to remission). While TMS is currently delivered in clinics by specialized staff, Ampa Health has developed a next-generation, portable TMS device suitable for deployment via telemedicine in remote or home settings, for populations who cannot easily attend clinics, such as late-stage palliative care patients, or patients with dementia or movement disorders.</p>
<p>Anatomiz3D Healthcare Limited Firoza Kothari anatomiz3d.ca</p>
<p>Anatomiz3D provides 3D Printed patient specific anatomical models, custom cutting and drilling guides and implants from patient CT and MRI scans. It also sets up Point of Care labs, allowing in-house hospital lab set-ups run by Anatomiz3D and provides defect based education models for students to practice complex surgeries.</p>
<p>Arterial Solutions Mohammad Qadura entrepreneurs.utoronto.ca/startup/arterial-solutions/</p>
<p>Arterial Solutions is a medical device company that aims to introduce novel diagnostics for a variety of cardiovascular diseases. Our first product, Artery Alert, is the first-ever blood test for peripheral arterial disease (PAD). This test will help physicians diagnose PAD in a timely manner, improve the quality of life of patients, and significantly curtail healthcare expenditure.</p>

Presenters and Exhibitors

Aufero Medical

Daniel Gelman

Aufero Medical's catheter stabilizing technology will improve the effectiveness of atrial fibrillation ablation therapy. Our unique, plug-n-play accessory device attaches easily to commonly used ablation catheters and provides on-demand contact stability. Designed with electrophysiologists, our product is intuitive, user-friendly, and has minimal impact on regular procedure workflows, making it an essential addition to any EP catheter lab.

Bay Area Research Logistics

Kaitlin Guarasci

bayarearesearchlogistics.com

Finding a supply chain solution that is right for your clinical trial can be a challenge and will likely not get simpler any time soon. This presentation will highlight at a high-level what goes into planning for and delivering a study drug, given the global reach of today's clinical trials. Consequently, it is important to be aware of some common elements associated with outsourcing to decrease risk and increase success when partnering with a logistics partner.

Bold Therapeutics Inc.

Michelle Jones

bold-therapeutics.com

Bold Therapeutics is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia founded to develop and commercialize BOLD-100, a first-in-class metallothiopyridine being developed for the treatment of advanced cancers. BOLD-100 is the most clinically advanced ruthenium-based therapeutic in development and is currently being studied in a global Phase 2 trial for the treatment of patients with advanced gastrointestinal cancers. Bold Therapeutics is now embarking on a Canadian-led clinical trial evaluating BOLD-100 in combination with standard of care for advanced sarcomas.

Canurta

Akeem Gardner

canurta.com

Canurta is a preclinical biotechnology company pioneering the discovery and production of novel, polyphenol-rich ingredients to improve chronic disease prevention and recovery for humans and animals. Our ingredients enhance the functionality of foods, wellness products and biopharmaceuticals.

CardioSTAT by Icentia

Michele Bischof

cardiostat.com

A turnkey ECG monitoring solution from end to end delivering high-quality results while streamlining workflow. CardioSTAT solution offers complete flexibility for decentralized and hybrid clinical trials to lower cost and improve patient enrolment.

Cloud DX Inc.

Neil Fraser

clouddx.com

Cloud DX supplies a complete Remote Patient Monitoring, Virtual Care Platform that connects patients to the care continuum from home. The Connected Health Platform by Cloud DX is able to monitor patient vital signs both episodically and continuously, facilitate questionnaires, drive patient engagement and conduct virtual visits by privacy-compliant chat and video. Published studies have shown that remote automated monitoring (RAM) with Connected Health improves patient outcomes and reduces ER visits and hospital admissions.

Presenters and Exhibitors

Cosm Medical

Goli Ameri

cosm.care

Cosm is a VC-backed medical device start-up in Toronto, developing a data-driven platform to create a personalized treatment for female pelvic floor disorders, which affect up to 50% of the female population. Cosm's platform leverages a novel medical imaging technique based on ultrasound imaging, as well as machine learning and 3D printing to address the needs of this underserved patient population. Since its inception in 2018, Cosm has grown from a team of 2 to 18 and is still expanding.

Cytokinetics

Richey Neuman

cytokinetics.com

Cytokinetics develops potential medicines to improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathy (HCM), and amyotrophic lateral sclerosis (ALS). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, we aspire to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.

Ensho

Kaveh Katebian

enshohealth.com

Ensho Health provides on-demand analysis of EHR data for medical research and clinical care. Healthcare providers connect to our data lab through integrations with Epic, Cerner, Accuro, OscarPro and other major EMR systems. Once connected, they can request one-time or recurring analyses of structured and unstructured data to match patients with clinical trials, enroll in real world studies, and for clinical quality improvement initiatives including with proprietary diagnostic algorithms.

ex-able

Lancy Qiu

ex-able.com

Limited evidence exists on the safety and accuracy of remote physical assessments in COPD which can result in delays to patients starting 'in-clinic' or tele-pulmonary rehabilitation (PR). Ex-able offers a high adherence platform that uses motion detection technology to aid the delivery of remote rehabilitation for chronic disease patients. Our focus is developing our technology to facilitate accurate remote assessment, allowing precise exercise prescription for COPD patients and a future predicting and preventing adverse events (e.g. falls)

FluidAI Medical

Nour Helwa

fluidai.md

FluidAI is a medtech startup that uses artificial intelligence to redefine postoperative care by utilizing the plethora of data within the body to enable data-driven intervention and care. Our first solution, Stream Platform™, makes use of novel sensors and machine learning algorithms to monitor patient recovery following gastrointestinal surgery, with the goal of early detection of complications such as postoperative leaks.

HelpWear

Brian McQuaker

helpwear.ca

HelpWear builds a 24/7 continuous, clinical grade ECG from a monitor worn on the patient's bicep. HelpWear's technology removes barriers for monitoring with traditional holter platforms and invasive implant monitoring devices

Presenters and Exhibitors

HOP Technologies

Marc-Antoine Pelletier

hoptech.ca

As a digital health company, HOP TECH participates in numerous clinical trials through university hospitals and pharmaceutical company collaborative agreements. Marc-Antoine Pelletier, HOP TECH's CEO will be presenting a short presentation on DISCOVERY an end-to-end digital clinical trial platform for the development of indication specific algorithms. HOP TECH business expansion with other Canadian and international partners is focused towards projects that require AI pipeline capabilities to accelerate the execution of clinical trials in respiratory diseases, type2-diabetes and heart failure.

Information Mediary Corporation

Joanne Watters

informationmediary.com

Including a smart packaging solution in your trial design may just be your number one cost-cutting decision to consider. Innovative designs are easily integrated into supply chains and provide real-time tracking of the investigational medicinal product (IMP). Efficiently managing drug supply and automating reconciliation processes are true end-to-end accountability measures that lead to improved patient safety.

JN Nova Pharma

John Gillard

jnova.com

Our lead therapeutic molecules are corona-viral neutralizing agents which trap and inhibit viral entry to the lungs and have full ACE2 enzyme replacement activity, supporting protection from acute kidney injury (AKI) and enhanced recovery from the acute respiratory syndrome (ARDS) and Pulmonary Fibrosis.

Kinarm

Anne Vivian-Scott

kinarm.com

Kinarm is a solution to the lack of precision and consistency in neurological assessment. With over 20 years of use by neuroscientists and clinician scientists across more than two dozen indications (neuro and non-neuro), Kinarm Labs are proven to provide the sensitivity, precision and confidence to measure subtle changes in brain function and dysfunction. Such validation is essential to authoritatively confirm the effect of candidate therapeutics.

Lumedi Inc.

Frank Naus

Lumedi.org

Lumedi delivers data platforms that are secure, privacy compliant, scalable, customizable, and reliable. Lumedi's EDC platform is perfect for efficient clinical trial data collection and storage by sites and directly from participants. Lumedi's simple, powerful and collaborative solutions are utilized by industry for Patient Support Programs (PSP) and as part of a Learning Management Systems (LMS).

Lumenix AIMS

Liam Ellis

aimsplatform.io

Lumenix is a leading provider of hardware, software, sensors, and AI technologies driving innovation in healthcare. Our latest technology, the Artificially Intelligent Monitoring System (AIMS), is a multi-functional AI platform technology designed to solve some of healthcare's most persistent data, quality, patient safety and resource management issues.

Mind-Easy

Dalia Ahmed

mind-easy.com

Culturally adapted and clinically validated self-help mental health solutions for diverse workforces.

Presenters and Exhibitors

Momentum Health

Evan Dimentberg

momentum.health

Momentum Spine, Momentum Health's first product, is a double-ended telehealth application to connect scoliosis patients to their physician securely and remotely. The mobile application employs smartphone cameras to recreate a true-to-scale three-dimensional model of the desired region from a simple video. Momentum Spine quantifies extra-spinal deformities (what we see from the outside) and correlates them to the Cobb Angle (what we can only see on X-rays) to predict the progression of the deformity and optimize clinical workflows.

Myant Inc.

Bastien Moineau

myanthealth.com

Myant is a Toronto company developing technology and medical devices using Textile Computing, from fundamental materials research to cloud computing. Our first Class 2 Medical Device, Skiin, uses conductive yarns and miniaturized electronics to comfortably and remotely collect ECG and other health metrics.

Noa Therapeutics

Carla Spina

noatherapeutics.com

Noa Therapeutics is a preclinical biotech company leveraging a systems biology approach to accelerate the design of tailored multimodal solutions for complex inflammatory diseases. Leveraging their discrete expertise in skin and wound therapeutics, Noa's scientific entrepreneurial team are advancing a first-use case in Atopic Dermatitis. By simultaneously addressing three constructive therapeutic targets, Noa's multimodal therapies will address a range of unmet needs enabling expansion into applications for systemic inflammatory diseases.

nVIGORus

Steven Grover

Nvigorus.com

Estimating the risk of dementia can support shared decision making to engage high risk individuals to reduce their risk through targeted prevention strategies (both lifestyle and pharmacotherapy). Using artificial intelligence (AI), and UK Biobank data, we have developed a validated dementia risk assessment (AUC 85%) that does not require biometric tests, imaging, or clinical evaluations. The HealthyBrainAge calculator is currently being evaluated in a proof-of-concept study (Funded by Innovative Solutions Canada) to engage federal employees to reduce their dementia risk using an online health promotion program (Nvigorus.com).

PhysioBiometrics Inc.

Nancy E. Mayo

physiobiometrics.com

PhysioBiometrics Inc. is a company dedicated to developing accessible technologies for people with movement vulnerabilities so they can move BETTER to move MORE. The pivotal technology is the Heel2Toe™ sensor that clips to the side of the shoe and provides real-time auditory feedback for a good step, one in which the gait cycle starts with a strong heel strike. Dopamine driven reward-feedback loop harnesses the power of the brain to stamp in a more normal gait cycle making walking better, faster, more efficient, and safer.

Qidni Labs

Morteza Ahmadi

qidni.life

Qidni Labs is making dialysis super accessible for patients with kidney failure. During our presentation, we will be covering our main product, Qidni/D, which is a nearly waterless, portable and cloud-enabled dialysis system that will enable patients to perform treatment anywhere at any time. We will also provide background on the progress the company has made to date and the exciting plans the company has for the future.

Presenters and Exhibitors

Qu Biologics

Hal Gunn

qubiologics.com

Qu Biologics' novel immunomodulation platform is designed to restore innate immune function in a targeted organ to prevent and treat a wide range of diseases, including cancer, chronic inflammatory diseases, and infections. Designed to train innate immunity in a safe and targeted way, Qu has completed four Phase 2 studies and is initiating two new randomized placebo-controlled studies in immunosenescence and in post-operative immune suppression in late-stage colon cancer. Qu's platform has transformative potential across a range of important diseases.

Rhythm Biotherapeutics

Darryl Davis

Rhythm Biotherapeutics is a pre-clinical stage biotechnology company developing exosome-based therapeutics to prevent and treat abnormal heart rhythms. Exosomes are therapeutic microparticles secreted by cells that repair atrial tissue to prevent atrial fibrillation and reduce the risk of stroke. Rather than wait to treat arrhythmias after they occur, Rhythm Biotherapeutics prevents the underlying inflammatory process that triggers post operative atrial fibrillation.

Roche Diagnostics Canada and University of Ottawa Heart Institute

Peter Liu

rochecanada.com

Diagnostic biomarkers such as IGFBP7 for heart failure, vascular impairment, and cognitive impairment.

Rogue Research Inc.

Roch Comeau

rogue-research.com

Rogue Research was established 22 years ago and developed the Brainsight neuronavigator which assists over 1000 laboratories around the world with the use of non-invasive brain stimulation for human brain mapping, cognitive neuroscience as well as neurological and psychiatric research. We have evolved with our customers to include a next-generation transcranial magnetic stimulator and robotic positioner. This integrated solution will improve the quality of clinical trials and provide a viable path for widespread clinical deployment.

Ruh Corp.

Humeyra N. Celebi

ruhapp.io

Ruh is a mindfulness app. It integrates Islam and psychology with technology to promote mental well-being. We are seeking to evaluate the efficacy of our content through randomized controlled trials.

Sinoveda Canada Inc.

Yun K. Tam

sinoveda.com

Sinoveda is a drug discovery company focusing on developing combination drug therapies derived from botanicals. Using its AI assisted platform technology, SCI-2213, derived from a medical food, was developed. Preliminary experience in 24 human subjects showed that SCI-2213, after two days of treatment, is effective in alleviating 11 long COVID symptoms, which include cough, fatigue, brain fog, taste and smell

Presenters and Exhibitors

St. Joseph's Healthcare

Mackensy Bacon

research.stjoes.ca

The Research Institute of St Joe's supports high-impact research with fulsome, personalized solutions to clinical trial management including expert contract negotiation, finance planning and reporting, information technology infrastructure, quality assurance, knowledge mobilization, laboratory infrastructure including wet lab space and more. Our unique, collaborative approach, combines the talents of over 700 world-class clinical researchers and research support teams with the cutting-edge resources of St Joseph's Healthcare Hamilton. Together we support the growth of research and innovation within St. Joseph's Healthcare Hamilton and across the St. Joseph's Health System to improve the care of over 1 million members of our community each year.

Syantra inc.

Kristina Rinker

syantra.com

Syantra has a blood test for breast cancer detection (Syantra DX Breast Cancer) that is available on the market across Canada and provided through our CPSA accredited laboratory. The test is used as a part of the breast cancer screening process, is complementary to imaging, and has 92% accuracy.

TBI Finder Inc.

Michael Noseworthy

tbifinder.com

TBIfinder is a data analytics company specializing in machine learning algorithms for personalized diagnostics of brain MRI scans. Whenever the brain "looks normal" on routine head MRI we are able to identify regions of both structural and functional abnormality and grade the severity of injury/disease. Using our MRI scanning protocol, doable on any 3T MRI, we can provide answers where previously there were none.

Tenomix

Saumik Biswas

tenomix.com

Tenomix is a fast-growing medical technology startup that is targeting a serious problem in the colon cancer staging process: the manual lymph node search process. We have developed a novel platform technology (integrates robotics, ultrasound imaging & AI/ML) that will automate the existing manual lymph node search process in surgically removed colon cancer tissues, making the process less labour intensive, less costly, and more reliable for pathology laboratories, resulting in better informed treatment decisions for cancer patients.

Therapeutic Monitoring Systems (TMS)

Andrew Seely

therapeuticmonitoring.com

TMS helps transform routine vital sign monitoring into valuable actionable clinical decision support, through the innovative patented combination of two novel technologies, variability analysis (analysis of patterns of variation of heart and lung rhythms) and artificial intelligence. We are introducing three novel software products, Extubation Advisor (first tool, Health Canada approval expected Q2/2023), Donation Advisor and Sepsis Advisor, that improve clinicians' capacity to determine optimal timing of a patient's safe liberation from the ventilator, determine a patient's candidacy for donation and transplantation after circulatory death and to determine where to admit a patient with infection (i.e. ward or intensive care unit).

Trimedix Therapeutics Inc.

Simon Jay

trimedixtherapeutics.com

Trimedix identifies, licences, develops and commercializes pharmaceuticals and devices for the Canadian market. Presently, Trimedix is preparing to launch Sibboran (landiolol HCL for inj.), an anesthesia/intensive care product with important properties for addressing super ventricular tachycardias and related arrhythmias.

Presenters and Exhibitors

Vasomune Therapeutics, Inc.

Shahid Ahmad

vasomune.com

Vasomune is a clinical stage Canadian biotechnology company developing a first-in-class vascular normalization investigational medicine targeting the Tie2 receptor. The Company's novel Tie2 agonist has multiple applications in which the underlying driver of mortality and morbidity is vascular endothelial instability, inflammation and vascular leak such as pneumonia/ARDS, sepsis, acute kidney injury and stroke/vascular dementia.

Vena Medical

Michael Phillips

venamed.ca

Vena Medical is providing physicians with access to the future of stroke treatment by getting the clot out on the first try every time. Beginning with the Vena Balloon Distal Access Catheter which has improved First Pass Effect from 44% to 64%. Next will be the Vena MicroAngioscope, the world's smallest camera, capable of going inside veins and arteries to help physicians treat stroke.

VIBRAINT Inc

Iliia Borishchev

vibrant.ai

VIBRAINT RehUp is a breakthrough brain-controlled rehabilitation robotics restoring mobility. Featuring a non-invasive brain-computer interface, VR and AI components, it was designed to assist paralyzed patients to regain movement - even in largely or totally immobilized limbs. Once approved by regulators, the system will be available on pay-by-use basis to rehabilitation clinics, centers and hospitals across North America.

VitalTracer

Azadeh Dastmalchi

vitaltracer.com

VitalTracer is focused on providing innovative personal healthcare products combining wearable technology and artificial Intelligence. We use biomedical sensors through the wrist/chest to measure vital signs continuously and store them in a secure cloud base environment that allows the patient to share them with their doctor or caregiver.

Xpan Inc.

Zaid Atto

xpanmedical.com

Xpan is developing a miniaturized access port (trocar) for minimally invasive surgery (MIS), which can enter the body at a smaller, less invasive size than current standard devices before expanding to larger, desired sizes, with minimal tissue trauma.

Zucara Therapeutics Inc.

Michael Midmer

zucara.ca

Zucara Therapeutics is a Toronto based clinical stage company developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with T1D and insulin-dependent Type 2 diabetes. The Company is planning a Phase 2 trial for ZT-01 after showing very compelling proof-of-concept in a Phase 1b trial last year in T1D patients. Zucara is interested in the support of the ACT Consortium to help advance clinical development for ZT-01 and expand into Type 2 diabetes as well as a long acting, weekly formulation, that would be more attractive to patients and commercial uptake.